Trials / NCT03328130
Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
Terminated Phase 1 / Phase 2 Gene therapy
Why it stopped: lack of financing
- Sponsor
- eyeDNA Therapeutics
- Treatment
- AAV2/5-hPDE6B
- Gene
- PDE6B
- Conditions
- Retinitis Pigmentosa
- Ages
- 13 Years to no upper limit
- Enrollment
- 19 participants
- Started
- 2017-11-06
- Main results expected
- 2025-06-30
- Results posted
- Not yet
- Record last updated
- 2025-12-18
What the study is testing
The study is a Phase I/II, monocentric, open-label, dose-ranging safety and efficacy gene therapy intervention by subretinal administration of AAV2/5-hPDE6B.
At least twelve patients 18 years of age or older, within four consecutive cohorts of patients, will be recruited.
Then at least four patients 13 years of age or older, within a fifth cohort, will be recruited.
Where it runs
France (1)
- Clinique Ophtalmologique, CHU de Nantes, Nantes